Visible symptom.
In guide 85, visible symptom changes the reading of is the website still representing the company?, because this redesign decision changes when the team can see the specific evidence, the buyer concern, and the launch risk attached to that part of the site.
Operating question: For guide 85, what would the team do differently about visible symptom if is the website still representing the company? had to be defended with evidence instead of opinion?